Ferric Phosphate Encyclopedia — Scientific Background

What Is Ferric Phosphate?

Ferric phosphate (CAS 10045-86-0), also known as iron(III) phosphate or ferric orthophosphate, is an inorganic iron salt composed of ferric iron (Fe³⁺) and phosphate anions (PO₄³⁻). It is chemically characterized by the molecular formula FePO₄·nH₂O, with an anhydrous molecular weight of 150.82 g/mol. The compound occurs as a pale yellow to off-white, odorless powder that is insoluble in water but soluble in acids. Ferric phosphate contains 26.0%–32.0% elemental iron.

Regulatory Status and Pharmacopoeial Standards

Ferric phosphate holds a well-established regulatory position as a food and pharmaceutical ingredient:

FDA GRAS Status — Ferric phosphate is Generally Recognized As Safe (GRAS) by the FDA under 21 CFR 184.1301 for use as a nutrient supplement in conventional foods, with no limitation other than current good manufacturing practice. It may also be used in infant formula in accordance with section 412(g) of the Federal Food, Drug, and Cosmetic Act.

FDA Substances Added to Food — Ferric phosphate is listed in the FDA Substances Added to Food database (formerly EAFUS) with CAS Registry No. 10045-86-0 and technical effect as a nutrient supplement. The Select Committee on GRAS Substances (SCOGS) has reviewed its safety.

Food Additive — Ferric phosphate functions as a nutrient supplement and is permitted in food in the United States, European Union, and other regions.

Physiological Functions of Iron

Iron is an essential trace mineral required for numerous physiological processes:

• Hemoglobin Synthesis — Iron is the central atom in the heme group of hemoglobin, enabling oxygen transport from the lungs to tissues

• Oxygen Transport — Iron-containing myoglobin facilitates oxygen storage and transport in muscle tissue

• Electron Transfer — Iron-sulfur clusters and heme groups participate in mitochondrial electron transport chain reactions

• Enzymatic Reactions — Iron is a cofactor for numerous enzymes involved in DNA synthesis, neurotransmitter production, and immune function

• Energy Metabolism — Iron-containing cytochromes are essential for ATP production

Mechanisms of Action and Absorption

Conventional Iron Absorption Pathway

Iron absorption from ferric phosphate follows the normal physiological pathway for non-heme iron. Ferric iron (Fe³⁺) must first be reduced to ferrous iron (Fe²⁺) by duodenal cytochrome b (DcytB) or dietary reducing agents such as vitamin C before it can be transported across the enterocyte membrane by the divalent metal transporter 1 (DMT1). Once inside the enterocyte, iron is either stored as ferritin or transported across the basolateral membrane by ferroportin into the bloodstream, where it binds to transferrin for distribution to tissues.

liposomal Absorption Pathway

Liposomal encapsulation provides a fundamentally different absorption mechanism. Once ingested, liposomes remain stable in the stomach and are absorbed intact in the small intestine via M cells, primarily in the duodenum, through endocytosis or membrane fusion. Inside enterocytes, iron is released and enters the normal intracellular iron pool. The liposomal delivery system bypasses the regulated DMT1 absorption pathway and provides an alternative route of cellular entry.

Particle Size and Bioavailability

The solubility of ferric phosphate in 0.1N HCl is the parameter that correlates most highly with its bioavailability (log10 solubility, R² = 0.93, p = 0.008). Research has demonstrated that nanoscale iron pyrophosphate (a related iron phosphate compound) with a hydrodynamic diameter of approximately 120 nm exhibited a relative bioavailability of 103%, significantly surpassing that of micron-sized iron pyrophosphate (59%). For ferric pyrophosphate in extruded rice, micronized particles (0.5 μm) achieved a relative bioavailability of 95% compared to ferrous sulfate, while larger particles (2.5 μm) achieved 70%, and regular-sized particles achieved only 45–58%.

The Bioavailability Challenge

Despite iron's essential physiological functions, conventional ferric phosphate presents significant absorption limitations. The compound is water-insoluble, and its limited solubility results in a low relative bioavailability compared to soluble iron salts such as ferrous sulfate. The relative bioavailability of ferric orthophosphate in humans is estimated to be between 25% and 32%, with commercial samples varying widely.

These limitations have driven the development of advanced delivery systems, including micronization, nanoparticle modification, and liposomal encapsulation. Among these, liposomal encapsulation has emerged as one of the most effective strategies for enhancing ferric phosphate bioavailability and therapeutic efficacy.

Liposomal Ferric Phosphate

Liposomal encapsulation of ferric phosphate provides a fundamentally different delivery mechanism from conventional forms. The phospholipid bilayer surrounds the iron-phosphate complex, forming a protective shell that enhances absorption and reduces gastrointestinal irritation. This delivery system:

• Enhances iron bioavailability through endocytosis and membrane fusion

• Achieves encapsulation efficiency up to 89.01%

• Protects iron from interactions with food components and stomach irritation

• Minimizes metallic taste and protects iron from oxidation

• Provides better gastrointestinal tolerance and compliance

Liposomal iron is prepared by the microencapsulation method by entrapping micronized iron inside the liposomal layer. Liposomal Ferric Pyrophosphate reaches peak plasma level faster than conventional iron salts, reaching maximum level after 2 hours of supplement consumption, which guarantees greater efficacy of the element for all metabolic processes in comparison to traditional iron. The formulation traps iron with over 85% encapsulation efficiency, keeping it protected and available. Its particles (500–2000 nm) stay dispersed thanks to a strong surface charge (zeta potential beyond ±30 mV), which prevents clumping and keeps quality stable on the shelf.

Clinical Evidence

Iron Deficiency Anemia Prevention in Children

A randomized controlled trial evaluated oral liposomal ferric phosphate versus ferrous sulfate for intermittent iron prophylaxis in children aged 6–59 months. Forty children in each group received 20 mg elemental iron twice weekly for 3 months. The liposomal iron group showed significant improvements in mean hemoglobin (p < 0.0001), serum iron (p = 0.0444), TSAT (p = 0.008), MCHC (p = 0.0491), and RDW (p = 0.0225) levels. At follow-up, the liposomal iron group had greater improvements in mean hemoglobin [LFP: 0.76 (0.67); FS: 0.16 (0.60) g/dL] and serum iron [LFP: 22.93 (29.51); FS: 9.72 (27.37) μg/dL] levels. The liposomal iron group experienced fewer side effects and better compliance (77% vs. 68.9% of the doses administered). The study concluded that oral liposomal ferric phosphate is effective and safe, and shows good compliance with iron deficiency anemia prevention in children aged 6–59 months.

Pediatric Chronic Kidney Disease Anemia

A single-center, open-label, randomized controlled trial evaluated 68 CKD stage 3–5 participants aged ≤14 years not on hemodialysis. Participants were randomized into conventional oral iron or liposomal iron and assessed after 12 weeks. Hemoglobin increased by 1.2 g/dL in the liposomal iron group versus 0.6 g/dL in the conventional iron group. Serum iron significantly increased in the liposomal group (55.7 to 70.7 mcg/dL, p = 0.03). TSAT improved significantly in the liposomal group (22.6% to 30.2%, p = 0.05). Adverse event incidence was lower in the liposomal iron group (19.4%) compared to the conventional iron group (43.7%).

Food Fortification — Rice

Ferric pyrophosphate was found to be the only acceptable iron fortificant for extruded rice because all other compounds (electrolytic iron, encapsulated ferrous sulfate, iron EDTA, and ferrous sulfate) colored the rice brown or gray. This makes ferric phosphate particularly valuable for rice fortification programs, where sensory neutrality is critical for consumer acceptance.

Iron Bioavailability of High Surface Area Ferric Phosphate

A clinical trial (NCT03660462) is evaluating the iron bioavailability of high surface area ferric phosphate (HiFe) compared to ferrous sulfate-fortified rice and ferric phosphate-fortified rice in women with low iron stores.

Safety and Regulatory

Ferric phosphate is generally well tolerated and has a favorable safety profile. It is affirmed as Generally Recognized As Safe (GRAS) by the FDA under 21 CFR 184.1301 for use as a nutrient supplement in conventional foods and infant formula. The Select Committee on GRAS Substances (SCOGS) has reviewed its safety and concluded that no change in GRAS status is necessary.

Liposomal encapsulation helps reduce the gastrointestinal side effects commonly associated with conventional iron salts. Adverse event incidence was lower in the liposomal iron group (19.4%) compared to the conventional iron group (43.7%) in a pediatric CKD trial. Iron status should be monitored through hemoglobin, ferritin, and transferrin saturation to guide dosing, as even well-tolerated forms should not be supplemented without confirmed deficiency due to the risks of iron overload.

Ferric phosphate is widely commercialized as a dietary supplement ingredient, food additive, and pharmaceutical agent. It is monographed in the Food Chemicals Codex (FCC), European Pharmacopoeia, and FAO/WHO Codex Alimentarius. Testing protocols must adhere to international standards including USP, European Pharmacopoeia, and FAO/WHO Codex Alimentarius. Formulators should verify local regulatory requirements prior to market entry.

This product is intended for research, nutraceutical, and functional food applications. Not intended to diagnose, treat, cure, or prevent any disease.

69$/KG